53 results about "Intestinal cell" patented technology

The invention provides a method for evaluating drug enterotoxicity in vitro through an intestinal organ model, and relates to the field of biological medicine. Comprising the following steps: preparing six different culture media, culturing the hESC by using the different culture media, inducing the hESC to respectively perform directional endoderm cell differentiation, posterior intestinal bulb differentiation, intestinal organ differentiation and intestinal organ maturation, and evaluating the drug enterotoxicity by using a prepared intestinal organ model. The intestinal organ model prepared by the invention is similar to human intestinal cells in composition, can accurately reflect the toxic effect of the medicine in the physiological environment in the human body, can be repeatedly obtained in quantity, and avoids clinical risks and ethical constraints; the sensitivity of drugs with different enterotoxicity can be reflected through cell viability, and the method is suitable for rapid evaluation of in-vitro high-flux drug enterotoxicity.

The invention discloses a liver-protecting beverage containing a composite plant exosome with optimized antioxidant capacity. The liver-protecting beverage comprises a plant exosome solution and a liver-protecting component, the plant exosome solution is a silybum marianum exosome solution and at least two of a Pingyin red rose exosome solution, a radix puerariae exosome solution, a turmeric exosome solution and a dandelion exosome solution; the liver protection component is at least one of silybum marianum micro-capsule powder, a radix puerariae extract, corn peptide, a dandelion extract and S-acetyl-L-glutathione. Hydroxyl and amido on small molecules are combined with lipid structures on the surfaces of multiple plant exosomes, small molecule active ingredients are combined through adsorption or reaction on the surfaces of the lipid structures of the exosomes, the oxidation resistance of the product can be improved, absorption of intestinal cells and probiotics is facilitated, cell metabolism is promoted, and then the fatigue feeling is reduced.

The invention discloses an in-vitro drug intestinal permeability determination method based on a high-flux barrier chip, and belongs to the technical field of microfluidics and organ chips. The high-flux barrier chip adopts a three-layer structural design of a pore plate layer, a porous membrane layer and a channel layer; the porous membrane not only realizes physical separation of the pore plate layer and the channel layer, but also undertakes the core function of interlayer substance exchange, and by matching with a gravity flow driving system provided by the swing table, the fluid dynamic characteristics in the chip are guaranteed. The hole pitch of the chip is strictly matched with the standard of a commercialized pore plate, and the chip can be directly compatible with various conventional analytical instruments and has good universality. The method is suitable for determining the intestinal permeability of the passive transport compound which can be absorbed by intestinal cells. Compared with the prior art, the human intestinal cells are adopted to construct the chip model, animal experiments do not need to be carried out, related ethical disputes are thoroughly avoided, the whole operation process is simple and easy to implement, and the detection time is greatly shortened.

The invention provides a lactobacillus fermentation extraction method of marine red algae polysaccharide and application of the marine red algae polysaccharide, and the method comprises the following steps: mixing marine red algae powder with water, and carrying out pasteurization at 60-70 DEG C for 20-40 minutes; adding lactobacillus plantarum into the sterilized marine red algae turbid liquid, and performing fermentation culture to obtain a marine red algae fermentation mixed liquid; heating and extracting the marine red algae fermentation mixed solution at 85-95 DEG C for 1.5-2.5 hours, centrifuging, collecting supernate, carrying out rotary evaporation and concentration to 1 / 5 of the original volume, then adding ethanol, standing overnight, discarding the supernate, adding distilled water into precipitate for redissolving, and deproteinizing by using a Sevag method to obtain a polysaccharide solution; and dialyzing the polysaccharide solution, and concentrating and freeze-drying the dialysate to obtain the marine red algae polysaccharide. According to the method, the low-molecular-weight modified polysaccharide is obtained through lactobacillus plantarum fermentation, extraction and purification, and the low-molecular-weight modified polysaccharide is high in sulfate group content, loose in structure, capable of remarkably inhibiting AGEs-induced intestinal cell oxidative stress and inflammatory reaction, capable of being used for preparing the glycosylation injury resisting medicine and good in industrialization prospect.

The application relates to application of iron-nitrogen doped graphene in preparation of anti-radioactive enteritis drugs and belongs to the technical field of biological medicines. ZIF-8 powder, 1,10-phenanthroline powder, iron (II) acetate powder and a grinding medium are placed in a closed container to perform mechanical ball milling treatment to obtain a mixed powder; under the protection of inert gas, the mixed powder is placed in a preheated tube furnace to perform pyrolysis treatment, and is cooled to room temperature to obtain iron-nitrogen doped graphene. The iron-nitrogen doped graphene has NADH oxidase-like activity, can directly catalyze the conversion of NADH into NAD + , can rapidly supplement NAD + depletion caused by radiation, can enhance PARP-dependent DNA damage repair, can reduce the generation of active oxygen (ROS), can reduce intestinal cell death and can protect the integrity of intestinal structure, and can realize efficient protection of radioactive enteritis. Moreover, the problem of low-efficiency biosynthesis of NAD + supplementation in existing radioactive intestinal injury protection technologies is solved.

The invention discloses a medicine for relieving side effects of gastrointestinal tracts caused by nintedanib, a medicine for preventing or treating pulmonary fibrosis and application of stachyose, and belongs to the technical field of medicines. The medicine taking the stachyose as the active ingredient can effectively relieve gastrointestinal tract side effects caused by the nintedanib, for example, intestinal mucosa lesions caused by the nintedanib can be obviously relieved, for example, intestinal mucosa tissue structure abnormity, intestinal cell proliferation activity reduction, intestinal cell apoptosis increase, intestinal tissue inflammatory factor gene expression level up-regulation and the like.

The invention belongs to the technical field of animal nutrition and feed, discloses an application of a Fuzhuan tea extract in prevention of vomitoxin-caused piglet health injury, and particularly relates to an application of the Fuzhuan tea extract as a feed additive in prevention or improvement of piglet health injury. The feed additive can effectively reduce negative effects on weaned piglets caused by excessive vomitoxin in the feed, wherein the negative effects comprise growth performance reduction, diarrhea rate increase, intestinal morphology damage, intestinal cell proliferation inhibition, intestinal epithelial barrier injury, immune disorder, abnormal liver function and excessive oxidative stress and inflammatory response.

The invention discloses a tooth-benefiting xylitol tablet candy and a preparation method thereof. The tooth-benefiting xylitol tablet candy is prepared from the following raw materials: xylitol, modified sodium alginate, HPMCP-genipin, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate. After the HPMCP-genipin enters the enteric cavity, the shell is dissolved, the L-glutamine and the anhydrous dextrose maintain and stabilize the osmotic pressure of intestinal cells, the genipin of the inner core and the primary amine group on the molecular chain of the modified sodium alginate are covalently crosslinked to form a gel network to wrap the xylitol, and meanwhile, the gel network absorbs water to form a local isotonic environment. A gel network wrapping xylitol enters a large intestine and is dissolved under the action of coliform bacteria, and galactooligosaccharide selectively stimulates the growth of bacteria methanogens capable of utilizing hydrogen, so that the total volume and partial pressure of gas in the intestinal tract are reduced. The microcrystalline cellulose improves the viscous component of the modified sodium alginate, and the colloidal silicon dioxide reduces the shearing and extrusion on the HPMCP-genipin in the tabletting process.

The invention relates to an establishment method of a high-fat induced intestinal organ injury model and an injury intervention method for the model. The establishment method comprises the following steps: step A, preparation: preparing colon cells, PBMC cells and an organ-like culture chip for later use; step B, colon barrier construction: inoculating colon cells to the surface of a barrier membrane on the lower side of a culture chip by using an organoid culture chip to obtain a colon barrier model; step C, constructing a co-culture model, and inoculating PBMC cells to the basal side of the colon barrier on the basis of the colon barrier to obtain a human colon barrier-PBMC co-culture model; d, constructing a damage model, and performing damage treatment on the co-culture model by using a treating fluid to obtain the damage model; according to the invention, the barrier function organ-like chip is used, a human intestinal cell-PBMC co-culture model is formed by utilizing human intestinal organs and PBMC cells, and OXLDL / palmitic acid can play a role in an injured intestinal organ barrier model and form a high-fat induced intestinal organ injury model through the prepared injury treating fluid.

The application relates to the technical field of bioengineering, and discloses a method for constructing an inflammatory bowel disease model, which comprises the following steps: constructing an inflammatory intestinal barrier by using intestinal cells from an inflammatory bowel disease patient; adding a stimulating solution containing immune cells and / or immune cell secretions into the inflammatory intestinal barrier, and carrying out co-culture to obtain an inflammatory bowel disease model. The inflammatory intestinal barrier constructed by using intestinal cells from an inflammatory bowel disease patient and adding immune components can retain the gene and cell shape characteristic expression characteristics related to IBD diseases, so that the model is closer to the pathological condition in the patient body; the actual in-vivo pathological damage progress is simulated, the model bionics is improved, the damage of the unbalanced immune cells in the IBD pathology to the intestinal tract is reproduced, and the potential drug targets can be discovered and verified. The application further discloses an inflammatory bowel disease model and an application thereof.

This invention relates to the application of a traditional Chinese medicine composition in the preparation of a drug for treating intestinal injury. The traditional Chinese medicine composition comprises: 50-150 parts of ginseng, 60-180 parts of polygonatum, 40-90 parts of atractylodes, 30-58 parts of sophora flavescens, 60-180 parts of ophiopogon japonicus, 60-110 parts of rehmannia glutinosa, 40-90 parts of polygonum multiflorum, 60-180 parts of cornus officinalis, 40-90 parts of poria cocos, 35-58 parts of eupatorium fortunei, 35-58 parts of coptis chinensis, 35-90 parts of anemarrhena asphodeloides, 35-58 parts of epimedium, 40-110 parts of salvia miltiorrhiza, 60-180 parts of kudzu root, 80-140 parts of litchi seed, and 40-90 parts of lycium chinense root bark. The above-mentioned traditional Chinese medicine composition can inhibit the expression of TNF, AGE-RAGE, TLR and IL-17 and the infiltration of macrophages. It also helps to regulate the proliferation and differentiation of intestinal cells, restore beneficial bacteria in the intestine, and significantly improve the barrier function of the intestine, thereby effectively improving the damaged intestinal function.

The application provides a kind of tea polyphenol ester-RNA self-assembly and hybrid nanovesicle of probiotic outer membrane vesicle and preparation method thereof, which first adjusts the hydrophilicity and hydrophobicity of tea polyphenol EGC through molecular modification strategy, and the EGC palmitate obtained by modification can directly wrap RNA and self-assemble into tea polyphenol ester-RNA nanovesicle, which has superior encapsulation capacity. Further introduce OMVs as intestinal targeted delivery carrier and fuse with RNA-tea polyphenol nanovesicle to form a structure stable hybrid vesicle. The hybrid vesicle of the application ingeniously integrates the advantages of both sides: tea polyphenol ester-RNA nanovesicle ensures efficient encapsulation of RNA, and OMVs provide natural protection for its translocation through gastrointestinal tract, and promote intestinal cell uptake with its inherent bioadhesion. This strategy can effectively promote the encapsulation and stabilization of oral RNA delivery.

The application discloses a composition for treating radiation enteropathy and application thereof, and belongs to the technical field of biological medicine, and solves the problem that there is no effective treatment drug for radiation enteropathy at present. The composition comprises puerarin, baicalein, berberine and glycyrrhetinic acid. The composition for treating radiation enteropathy can regulate Wnt / beta-catenin, NF-kappa B and Caspase-9 / 3 signal pathways and the like, promote the proliferation of intestinal cells after radiation damage, reduce the inflammation level of intestinal tissues after radiation, reduce the apoptosis of intestinal cells after radiation and the like, improve the radiation damage of intestinal epithelial cells, play an anti-radiation enteropathy role, and has a remarkable effect on treating radiation enteropathy.

This invention discloses a strain of *Lactobacillus paracasei* capable of converting cyanocobalamin and promoting its absorption, thereby enhancing brain nerve repair and improving cognition, and its postbiotic, belonging to the fields of microbial technology and pharmaceutical technology. The *Lactobacillus paracasei* CCFM1527 and its prepared postbiotic provided by this invention promote the growth of vitamin B1 in the host. 12 The neuroprotective effects of upregulating the expression of absorption receptors and converting CN-CbI to methylcobalamin include: (1) promoting the upregulation of Amnionless expression in intestinal cells (Caco-2); (2) converting CN-CbI to methylcobalamin; and (3) promoting the upregulation of Amnionless expression in mouse ileum. AMN Upregulation of gene expression (4) significantly increased the levels of vitamin B in mice. 12 (5) Significantly promotes the expression of MBP and PSD-95 proteins in mice; (6) Improves the decline in cognitive ability in mice, and has great application prospects.

This invention relates to the fields of biomedicine and food nutrition, specifically to the application of purple sweet potato anthocyanins in the preparation of products for preventing or improving intestinal aging. This invention demonstrates that purple sweet potato anthocyanins can significantly improve the degenerative changes and barrier fragility of the colon caused by natural aging, restore colonic crypt morphology and epithelial ultrastructure, and upregulate the expression of tight junction proteins and mucus barrier-related indicators. Furthermore, purple sweet potato anthocyanins can effectively enhance crypt proliferation activity and promote the differentiation of intestinal stem cells into secretory lineages (such as goblet cells and enteroendocrine cells). Its mechanism of action does not rely on direct anti-inflammatory pathways, but rather on remodeling intestinal flora metabolism (such as increasing short-chain fatty acids) and activating intestinal cell autophagy via the PI3K-Akt signaling pathway, thereby supporting the continuous renewal and maintenance of the intestinal barrier. This invention provides a new approach for the development and application of food-derived polyphenols targeting the gut to promote healthy aging.

The invention belongs to the technical field of microorganisms, and discloses a strain of lactobacillus plantarum which has the effects of resisting oxidation, detoxifying and relieving ulcerative colitis, and the preservation number of the lactobacillus plantarum is GDMCC (China General Microbiological Culture Collection Center) NO.66774. The strain has a free radical scavenging capability, can improve the antioxidant enzyme activity of intestinal cells, and can degrade endotoxin; meanwhile, the strain can regulate the immune balance of the organism, remodel the homeostasis of intestinal flora, promote the generation of acetic acid, propionic acid and butyric acid, effectively repair the damaged intestinal mucosal barrier, and improve the ulcerative colitis symptom from multiple dimensions in a synergistic manner. Therefore, the strain can be used for preparing functional foods, nutritional supplements and microecologics with the effects of resisting oxidation, expelling toxins, protecting intestines and preventing and treating ulcerative colitis.

The invention provides a method for amplifying norovirus by using an intestinal organ gas-liquid interaction model, and relates to the technical field of biological medicines. Comprising the following steps: preparing a culture medium, and inducing stem cell differentiation according to the prepared culture medium to form intestinal organs; placing the differentiated intestinal organs in Transwell for continuous culture, promoting maturation of the intestinal organs under the condition of a culture medium, and forming an intestinal organ gas-liquid interaction model; extracting the norovirus, infecting the intestinal organ gas-liquid interaction model by using the norovirus, and then detecting the amplification multiple of the norovirus. The intestinal organ gas-liquid interaction model prepared by the invention is similar to human intestinal cells in composition, can realize infection and amplification of the norovirus in vitro, can be repeatedly obtained in large quantities, avoids clinical risks and ethical constraints, and is suitable for research of norovirus in-vitro infection mechanism and drug screening.

A method for treating and / or improving inflammatory intestinal disease includes administering a composition to a patient suffering from inflammatory intestinal disease to be capable of effectively inhibiting the patient's intestinal bleeding, intestinal inflammation, and capable of achieving efficacies of repairing intestinal cells and intestinal wall structure. The composition contains an effective amount of bromelain and / or an effective amount of Bidens pilosa extract.

The invention discloses an intestinal cancer mouse model based on Par3L gene knockout and a construction method thereof. After sgRNA is designed to knock out a promoter and a first exon of a Par3L gene of a mouse, the progeny of the obtained gene knockout mouse can spontaneously form intestinal cancer along with the increase of age, and the progeny is accompanied with a tissue infiltration phenotype. The intestinal cancer mouse model constructed by the invention can cause abnormal mitosis of intestinal cells and influence the genome stability, a good model system is provided for further research on the occurrence mechanism of intestinal cancer, and the intestinal cancer mouse model has a wide application prospect.

The invention belongs to the technical field of animal bifidobacterium subsp. Lactis, and particularly relates to an animal bifidobacterium subsp. Lactis BL-33 and application thereof. The bifidobacterium animalis subsp. Lactis has the performance of targeted inhibition of Streptococcus parahaemolyticus, Enterobacter cancerogenus and Alloscedobacterium animalis, can effectively inhibit alpha-glucosidase, stimulate intestinal cells to generate glucagon-like peptide-1, can effectively improve the disease of a diabetic mouse, and has the advantages of being capable of improving the curative effect of the diabetic mouse, and the like. The composition can be used for preparing products for preventing and treating diabetes or assisting in reducing blood sugar.

While studies have been made on a method of selectively inducing differentiation from pluripotent stem cells into enterocyte-like cells, provided is an excellent and high-functionality enterocyte-like cell population that can be stably tested for multi-drug metabolism and permeability, and also provided an efficient method of producing cells. The method of inducing differentiation from pluripotent stem cells into enterocyte-like cells includes the following steps (1) and (2): (1) a step of inducing differentiation from pluripotent stem cells into definitive endoderm cells; and (2) a step of culturing the definitive endoderm cells in a system containing CHIR99021, followed by induction of differentiation into intestinal progenitor cells. A cell population of enterocyte-like cells is more effectively obtained by seeding and culturing enterocyte-like cells produced by the method of inducing differentiation, in a base material for organoid production or a base material for two-dimensional culture.

The invention provides an intestinal cell model as well as a preparation method and application thereof. According to the method, a Caco-2 / THP-1 cell co-culture system is constructed to simulate the dynamic interaction between epithelial cells and immune cells in human intestinal tracts, and finally comprehensive evaluation on digestion efficiency, absorption efficiency, bioavailability, metabolites, inflammatory reaction influence and the like of drugs, nutrient substances (such as milk powder) and other components is realized.

The invention belongs to the technical field of biological medicines, and particularly relates to application of butyric acid-producing enteromonas in prevention and treatment of senile deafness. It is found for the first time that the butyric acid producing enteromonas sp. Has a remarkable hearing protection effect in a senile deafness model; the action mechanism is mainly embodied in that by improving hearing threshold rise caused by aging, the structural integrity of cochlea hair cells is partially protected to relieve arrangement disorder and deletion of outer hair cells, and the number of inner ear spiral neuron ganglions and vascular stripe aging cells is effectively reduced; meanwhile, the high expression of Pvalb key genes and Parvalbumin in neurons and hair cells of spiral ganglions is up-regulated, so that the synergistic effect is achieved by enhancing the sound transmission muscle efficiency of the middle ear, improving the blood vessel microcirculation of the inner ear, stabilizing the hair cytoskeleton and protecting nerves. The invention provides a new candidate strain resource and an intervention target for preventing and treating senile deafness, and has important clinical application prospect and social value.

The invention provides a method for screening lysosomal storage disease related genes based on a caenorhabditis elegans lysosomal overload model and application of the method. The method comprises the following steps: constructing a transgenic nematode strain containing an intestinal specific promoter nhx-2p-driven CPL-1 and red fluorescent protein wrmScarlet fusion expression vector; intestinal cells are induced to secrete CPL-1:: wrmScarlet fusion protein into coelomic fluid, and the fusion protein is endocytosed and accumulated in lysosome by coelomic cells to form a quantifiable overload phenotype, and then gene expression is knocked down by adopting a feeding RNA interference technology; the red fluorescence signal intensity change of body cavity cells is observed under a stereoscopic fluorescence microscope so as to screen candidate genes for promoting or relieving lysosome storage, and meanwhile, the model can be used for drug screening, and has the advantages of direct observation through a low-power lens at a living animal level, high flux, quantifiability, convenience in operation and the like; and the long-standing key technical bottleneck in the field of lysosomal storage diseases is solved.

The invention provides a C2BBe1 intestinal cell reprogramming method and system, and aims to solve the technical problems of low reprogramming efficiency, unstable reprogramming result, difficulty in truly simulating in-vivo real conditions and difficulty in driving intestinal epithelial cell physiological morphology and differentiation maintenance in current intestinal tissue modeling. An in-vivo intestinal canal model and an in-vitro gas-liquid exchange interface model are constructed, real in-vivo conditions can be simulated, a crypt-villus topological structure can be reconstructed spontaneously, and spatial heterogeneity and cell lineage distribution of intestinal epithelium can be simulated truly. After specific mechanical stimulation characteristic verification of the intestinal canal at different development stages is carried out, a verification result is obtained, and actual in-vitro inoculation is carried out on the basis of the verification result. And finally undifferentiated cells can be directly reprogrammed, so that the dependence on pluripotent stem cells and a complex induction process in a traditional method is avoided, and the reprogramming efficiency and stability are remarkably improved.

The present application relates to the technical field of drug-loaded particles, and discloses a kind of drug-loaded stable curcumin composite nanoparticles and preparation method thereof, including rice protein enzymatic hydrolysate as carrier, load curcumin, and using chondroitin sulfate to stabilize the rice protein enzymatic hydrolysate load the curcumin, the curcumin composite nanoparticle encapsulation efficiency is 70%~90%, the mass ratio of the contained rice protein enzymatic hydrolysate and chondroitin sulfate is 1~5:1, the mass ratio of the contained rice protein enzymatic hydrolysate and curcumin is 8~12:1.In dissolved in gastric acid with pH 0.9~1.5, the protein in nanoparticle still keeps stable, and still can keep larger curcumin retention rate, particle size also keeps in nanometer, and nanometer particle size also makes nanoparticle easy to be taken up by intestinal cells, effectively improves bioavailability.

The invention relates to application of Metrnl in prevention and treatment of radioactive bowel diseases. The Metrnl is used for preventing and treating the radiation bowel disease for the first time, and the expression of the intestinal epithelial cell Metrnl is related to the radiation bowel disease. By establishing a Metrnl intestinal epithelial cell specific knockout and overexpression mouse model, it is proved that damage after irradiation is aggravated due to the fact that intestinal epithelial cells lack Metrnl, and a Metrnl intestinal specific overexpression mouse can relieve radiation damage. In a cell model, DNA damage caused by ionizing radiation after Metrnl knockdown is aggravated, the cell proliferation capacity is weakened, Metrnl overexpression can resist ionizing radiation damage, and METRNL recombinant protein has prevention and treatment effects on ionizing radiation damage. The invention proves that Metrnl has the effect of preventing and treating radioactive bowel diseases for the first time, and the protection mechanism of Metrnl is related to the reduction of DNA damage of intestinal cells.

The invention belongs to the technical field of organ chip models, and particularly discloses a liver and intestine chip model and a method for evaluating the influence of oligosaccharide on the liver through the liver and intestine chip model. The liver and intestine chip model comprises a multi-layer micro-fluidic structure, and the main body material of the multi-layer micro-fluidic structure is modified polydimethylsiloxane; the multi-layer micro-fluidic structure comprises an intestinal microcavity, a liver microcavity and a micro-channel connecting the intestinal microcavity and the liver microcavity, the intestinal microcavity is connected with similar intestinal cells, the liver microcavity is connected with similar liver cells, a window hole array is arranged at the bottom of the liver microcavity, grooves are formed in the corners of the liver microcavity, an elastic film is integrated at the bottom of the intestinal microcavity, and the elastic film is connected with the micro-channel. The elastic film is communicated with an external pneumatic driving system, and a micro-structure similar to intestinal villi is etched on the upper surface of the elastic film. By the adoption of the liver and intestine chip model and the method for evaluating the influence of the oligosaccharide on the liver through the liver and intestine chip model, the liver and intestine organ chip model can simulate the microenvironment of the intestine-liver axis in the body, and a more real and reliable platform is provided for studying the influence of the oligosaccharide on the liver.

The invention relates to the technical field of molecular biology and gene engineering. Mainly relates to a novel recombinant antibacterial peptide as well as a construction method and application thereof. The CM13 of the antibacterial peptide disclosed by the invention has better bacteriostatic and bactericidal effects on selected gram-positive and gram-negative standard strains, has the bacteriostatic concentration of 4-8 mu M, has ideal serum and pepsin stability, has lower toxicity to small intestine cells of mice and pigs, has efficient penetrability to the two kinds of intestinal cells, and has wide applicability. The recombinant antibacterial peptide CM38, the combined antibacterial peptide CM38-eGFP and the combined antibacterial peptide CM38-hEGF provided by the invention are all high in secretion amount, relatively high in antibacterial activity to selected standard pathogenic bacteria, low in hemolytic activity and improved in biological stability, the antibacterial concentration is 3.39-9.94 mu M, and technical support is provided for large-scale production of antibacterial peptide feed additives and engineering yeast preparations.

The invention provides a calcium ion signal research model for in-vivo nematode intestine preparation and a construction method, and relates to the technical field of biological model construction, and the construction method comprises the following steps: culturing nematodes; constructing a probe plasmid for transgenosis: synthesizing an nhx-2 promoter by a chemical synthesis method, and respectively connecting two ends of the promoter with Hind III and BamH I restriction enzyme cutting sites; then amplifying the YC3.60 by using a PCR (Polymerase Chain Reaction) technology; then, the promoter sequence is firstly inserted into the plasmid, and then YC3.60 is inserted behind the promoter. Genetically modified microinjection is adopted for nematodes, and then nematodes with green fluorescent protein in intestinal cells are obtained through screening. According to the application, YC3.60 is transferred into a nematode body in a transgenosis manner, and the fluorescent probe can be specifically expressed in intestinal cells after a promoter specifically expressed in the intestinal cells is used for connecting the gene transgene of the fluorescent probe protein into the nematode body. The specific calcium-regulated physiological behaviors of the constructed nematode intestinal cells can be used for researching calcium oscillation, periodic behaviors, intercellular calcium transfer and the like.